Dr. Phillip Chan of Cytosorbents ($CTSO) @ Stock News Now on Blood Purification Technology

Stock News Now on Blood Purification Technology

CytoSorbents Corporation (OTCBB: CTSO) is a critical care-focused therapeutic device company using blood purification to treat life-threatening illnesses. Its purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and adsorption. In March 2011, CytoSorb™, the Company's flagship product, achieved European regulatory approval as an extracorporeal cytokine filter, and can now be sold throughout the European Union (E.U.) under the CE Mark to be used in cases where cytokines are elevated. In this interview with Shelly Kraft of Stock News Now, Dr Chan explains how CytoSorb™ calms the cytokine storm to help patients rushed into the intensive care unit. Dr. Chan explains that CTSO has “29 issued patents on the technology”, and that CytoSorb™ is now available in the European Union: